Downloads
Abstract
Background: In Vietnamese clinical practice, studies on the effectiveness of ARNI (Sacubitril/Valsartan) are still limited. So, we conducted the study with two goals: Investigation of clinical and subclinical characteristics of patients with chronic HFrEF using ARNI and Evaluation of the dosage efficacy and safety of ARNI in these patients.
Methods: A cross - sectional description with follow - up was conducted on 69 patients hospitalized diagnosed: chronic heart failure with reduced left ventricular ejection fraction.
Results: Male were more than female, the male/female ratio was 2.16. The mean age was 60.69 ± 17.03 years old. The level of improvement of the NYHA class after treatment compared to before from the two dosage groups was statistically significant (p = 0.004). Reduce of NT-proBNP concentration was statistically significant with p < 0.01 (4931 pg/mL versus 3638 pg/mL). The left ventricular diastolic - systolic diameter and EF changed significantly (p < 0.01). There was no change in left atrial diameter and Creatinine concentration before and after treatment showed no significant change.
Conclusion: ARNI was effective in the treatment of chronic HFrEF: improving NYHA class, EF, LVDs, LVDd and reducing NT-pro BNP levels according to dose and with almost no significant side effects.
References
Chang HY, Feng AN, Fong MC, et al. Sacubitril/valsartan
in heart failure with reduced ejection fraction patients:
Real world experience on advanced chronic kidney
disease, hypotension, and dose escalation. J Cardiol.
;74(4):372-380.
Jaffuel D, Nogue E, Berdague P, et al. Sacubitril-valsartan
initiation in chronic heart failure patients impacts sleep
apnea: the ENTRESTO-SAS study. ESC Heart Fail.
;8(4):2513-2526.
Bộ Yt. Hướng dẫn chẩn đoán và điều trị suy tim mạn
tính. 2020.
Hội TmqgVN. Khuyến cáo của Hội Tim mạch quốc gia Việt
Nam về chẩn đoán và điều trị suy tim: Cập nhật 2022. 2022.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/
ACC/HFSA Guideline for the Management of Heart Failure:
A Report of the American College of Cardiology/American
Heart Association Joint Committee on Clinical Practice
Guidelines. Circulation. 2022;145(18):e895-e1032.
Kaluzna - Oleksy M, Kolasa J, Migaj J, et al. Initial clinical
experience with the first drug (sacubitril/valsartan) in a new
class - angiotensin receptor neprilysin inhibitors in patients
with heart failure with reduced left ventricular ejection
fraction in Poland. Kardiol Pol. 2018;76(2):381-387.
Nguyễn Thanh Huân, Lê Quốc Hưng, Trần Thị Mỹ Liên,
et al. Bước đầu đánh giá hiệu quả và an toàn của sacubitril/
valsartan ở các bệnh nhân suy tim có phân suất tống máu
giảm. Tạp chí Y học Thành phố Hồ Chí Minh - Phụ bản tập
, số 3. 2019:169-173.
DeVore A. D., Braunwald E., Morrow D. A., et al. Initiation
of Angiotensin - Neprilysin Inhibition After Acute
Decompensated Heart Failure: Secondary Analysis of the
Open-label Extension of the PIONEER-HF Trial. JAMA
Cardiol. 2020;5(2):202-207.
McMurray John J.V., Packer Milton, Desai Akshay S., et
al. Angiotensin - Neprilysin Inhibition versus Enalapril
in Heart Failure. New England Journal of Medicine.
;371(11):993-1004.
Kim HM, Kim KH, Park JS, et al. Beneficial Effect
of Left Ventricular Remodeling after Early Change of
Sacubitril/Valsartan in Patients with Nonischemic Dilated
Cardiomyopathy. Medicina (Kaunas). 2021;57(5).
Nguyễn Tri Thức, Kiều Ngọc Dũng, Lý Văn Chiêu. Nghiên
cứu tính an toàn và hiệu quả của sacubitril/valsartan trong
điều trị suy tim trên thực tiễn lâm sàng. Hội nghị Tim mạch
học Việt Nam. 2018.
Pascual - Figal D, Wachter R, Senni M, et al. NT-proBNP
Response to Sacubitril/Valsartan in Hospitalized Heart
Failure Patients With Reduced Ejection Fraction:
TRANSITION Study. JACC Heart Fail. 2020;8(10):822-
| Published | 20-08-2023 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | No. 89 (2023) | |
| Section | Original article | |
| DOI | 10.38103/jcmhch.89.14 | |
| Keywords | ARNI, suy tim mạn tính, suy tim EF giảm. ARNI, chronic heart failure, HF with reduced LVEF |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Journal of Clinical Medicine Hue Central Hospital